• news and publications | Enterprise Therapeutics | Treatment of respiratory diseases

PUBLICATIONS, NEWS & EVENTS

The discovery of novel TMEM16A potentiator compounds, presented at the Gordon research Conference, “Mucus & Mucociliary interactions”, Galveston, USA, February 2017

It is widely accepted that the composition of mucus in the CF…
February 1, 2017/by admin

Enterprise Therapeutics Announces £4 million ($5 million USD) Fundraising

Brighton, UK – 10th November, 2016: Enterprise Therapeutics…
November 10, 2016/by admin

Enterprise Therapeutics appoints Dr John Ford as CEO

Brighton, UK – October 17, 2016 - Enterprise Therapeutics Ltd,…
October 17, 2016/by admin

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at North America Cystic Fibrosis Conference, Orlando, October 2016

The TLR5-agonist flagellin (FLG) is the key protein component…
October 1, 2016/by admin

Pharmacological characterisation of TMEM16A regulators, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

TMEM16A was recently identified as a calcium-activated chloride…
March 2, 2016/by admin

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

A screen of microbial-derived products using a 3D model of the…
March 1, 2016/by admin

New drug discovery company announces additional funding to tackle chronic respiratory disease

Brighton, Sussex, May 20th 2015 - ENTERPRISE THERAPEUTICS Ltd,…
May 20, 2015/by admin

World class drug discovery team launches new company to tackle chronic respiratory disease

Brighton, Sussex, February 12th 2015 - ENTERPRISE THERAPEUTICS…
February 12, 2015/by admin

Enterprise is a clinical stage biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are currently in clinical trials.

Learn more